Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study.
Times cited: 121
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Journal of Clinical Oncology.
Times cited: 344
Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets.
Times cited: 119